Glycemic Excursions in Type 2 Diabetic Patients Treated With Vildagliptin and Metformin Versus Glimepiride and Metformin
Type 2 Diabetes · Hypoglycemia
Enrolment: 40 · Results not recorded
Loading the evidence…
Drug · DPP-4 inhibitor (INHIBITOR); direct interaction, disease efficacy true
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Type 2 Diabetes · Hypoglycemia
Enrolment: 40 · Results not recorded
Type 2 Diabetes
Enrolment: 67 · Results not recorded
Diabetes Mellitus, Non-Insulin-Dependent
Enrolment: 16 · Results not recorded
Diabetes Mellitus, Type 2
Enrolment: 370 · Results not recorded
Diabetes Mellitus, Type 2
Enrolment: 3118 · Results not recorded
Renal Transplantation · Diabetes
Enrolment: 186 · Results not recorded
Diabetes Mellitus, Type 2
Enrolment: 22 · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Hepatic ischaemia/reperfusion with remote renal injury
Vildagliptin significantly improved the biochemical markers of remote renal injury and the histopathological changes after hepatic ischaemia/reperfusion, and blocked the upregulation of renal TGF-beta/Smad/alpha-SMA mRNA expression.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.
Model: Systemic endotoxaemic lung injury and subsequent post-acute lung injury pulmonary fibrosis induced by intraperitoneal lipopolysaccharide from Escherichia coli O55:B5, 5 mg/kg for five consecutive days
Repeated lipopolysaccharide exposure increased CD26 expression in pulmonary vascular endothelial cells and produced prominent interstitial pulmonary fibrosis with increased endothelial-to-mesenchymal transition. Vildagliptin attenuated the fibrosis, reduced mesenchymal marker gene expression, resto…
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.